...
首页> 外文期刊>Journal of viral hepatitis. >Severe weight loss in HIV / HCV-coinfected patients treated with interferon plus ribavirin: incidence and risk factors.
【24h】

Severe weight loss in HIV / HCV-coinfected patients treated with interferon plus ribavirin: incidence and risk factors.

机译:接受干扰素加病毒唑治疗的HIV / HCV合并感染患者的严重体重减轻:发生率和危险因素。

获取原文
获取原文并翻译 | 示例

摘要

Weight loss is reported by more than 20% of hepatitis C virus (HCV)-monoinfected patients treated with the peg-interferon (peg-IFN) and ribavirin combination. The aim of this study was to determine the incidence and risk factors of severe weight loss (> or =10%) in human immunodeficiency virus (HIV) / HCV-coinfected patients participating in a randomized, controlled 48-week trial comparing peg-IFN alpha 2b plus ribavirin with IFN alpha-2b plus ribavirin. Univariate and multivariate analyses were used to identify links with antiretroviral treatments, anti-HCV therapy and clinical and laboratory findings. One hundred eleven (28.9%) of 383 patients who received at least one dose of anti-HCV treatment subsequently had severe weight loss. Among patients who took at least 80% of the planned total dose, severe weight loss occurred in 74 patients (32.7%). In multivariate analysis, age >40 years [hazard ratio (HR), 1.59; 95% CI 1.09 to 2.31; P = 0.016], body mass index (BMI) >22 (HR, 1.72; 95% CI, 1.16 to 2.55;P = 0.0069), peg-IFN alpha-2b (HR, 1.82; 95% CI, 1.24 to 2.69; P = 0.0022) and female sex (HR, 1.60; 95% CI, 1.05 to 2.43; P = 0.027) were associated with severe weight loss. In contrast, patients taking non-nucleoside reverse transcriptase inhibitors (NNRTI)-containing antiretroviral regimens were less likely to lose weight (HR, 0.62; 95% CI, 0.39 to 0.96; P = 0.034). Lipodystrophy tended to occur more frequently in patients who had severe weight loss than in the other patients (26.1%vs 17.6%; P = 0.0682) and patients whose weight loss >5% persisted 24 weeks after the completion of anti-HCV therapy (n = 58 / 111) were more likely to be receiving stavudine-based antiretroviral therapy, suggesting that mitochondrial toxicity plays some role in weight loss. These findings show that severe weight loss is a frequent side effect of anti-HCV therapy in HIV / HCV-coinfected patients. The underlying mechanisms remain to be identified.
机译:据报道,接受聚乙二醇干扰素(peg-IFN)和利巴韦林联合治疗的丙型肝炎病毒(HCV)单感染患者体重减轻。这项研究的目的是确定人免疫缺陷病毒(HIV)/ HCV合并感染的患者中严重体重减轻(>或= 10%)的发生率和危险因素,该患者参加了一项对peg-IFN进行比较的随机对照研究,为期48周α2b加利巴韦林与IFN alpha-2b加利巴韦林。使用单变量和多变量分析来确定与抗逆转录病毒治疗,抗HCV治疗以及临床和实验室发现之间的联系。 383例接受至少一剂抗HCV治疗的患者中有111例(28.9%)随后出现了严重的体重减轻。在至少服用计划总剂量80%的患者中,有74位患者(32.7%)发生了严重的体重减轻。在多变量分析中,年龄> 40岁[危险比(HR),1.59; 95%CI 1.09至2.31; P = 0.016],体重指数(BMI)> 22(HR,1.72; 95%CI,1.16至2.55; P = 0.0069),peg-IFN alpha-2b(HR,1.82; 95%CI,1.24至2.69; P = 0.0022)和女性(HR,1.60; 95%CI,1.05至2.43; P = 0.027)与严重的体重减轻相关。相反,服用含非核苷类逆转录酶抑制剂(NNRTI)的抗逆转录病毒疗法的患者减肥的可能性较小(HR,0.62; 95%CI,0.39至0.96; P = 0.034)。严重体重减轻的患者比其他患者(26.1%vs 17.6%; P = 0.0682)和体重减轻> 5%的患者在完成抗HCV治疗后24周内持续出现脂肪营养不良(n = 58/111)更有可能接受基于司他夫定的抗逆转录病毒疗法,这表明线粒体毒性在减肥中起一定作用。这些发现表明,在HIV / HCV合并感染的患者中,严重的体重减轻是抗HCV治疗的常见副作用。潜在机制尚待确定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号